arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Immunocore Holdings plc

IMCR
$32.45 ▲ +0.27 (+0.84%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
17 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Immunocore Holdings plc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7B
Dividend Yield
Revenue Growth 18.3%
Op. Margin -2.6%
ROIC -1.1%
FCF / Share $0.30
Trailing P/E
Price / Book 4.0x
FCF Yield 0.9%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

17-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$115.93M
↑ +18.3%
Net Income Profit after all expenses
$12.97M
↑ +158.2%
Operating Margin Operating profit as % of sales
-2.6%
↓ -137.9% 14th
FCF / Share Free cash flow per share
$0.30
↑ +196.9%
Long-Term Debt Long-term obligations
$438.69M
↓ -3.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
16
Returns
35
Financial Health
38
Cash Quality
37

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 17 quarters